Managers / Q1 2022 · view latest →

Decheng Capital Management III (Cayman), LLC

CIK 0001747821 · PO BOX 309, UGLAND HOUSE, GRAND CAYMAN, E9, KY1-1104 · 345-949-8066

Reported Value

$326M

Q1 2022

Positions

Filings on Record

2019–present window

Filed

May 10, 2022

original filing

Summary

Decheng Capital Management III (Cayman), LLC reported $326M in U.S.-listed holdings across 24 positions for Q1 2022.

Its largest position, HLTHQ, represents 17.8% of the portfolio.

Portfolio Metrics

Top-10 Concentration

+82.7%

share of reported value

Largest Position

+17.8%

Cue Health

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value

Portfolio Composition

By security type

Common Stock · 73.1% · $238M
Other · 26.9% · $88M

Quarter-over-Quarter Changes full breakdown →

Issuer	Move	Share Δ	Shares now	Value Δ	Value now
HLTHQ Cue Health Inc.	NEW	+8.98M	8.98M	+$58M	$58M
ILMN Illumnia, Inc.	NEW	+154.2K	154.2K	+$54M	$54M
NVLSEUR Alpine Immune Sciences, Inc.	NEW	+4.71M	4.71M	+$42M	$42M
Arcus BioSciences, Inc.	NEW	+869.8K	869.8K	+$27M	$27M
10x Genomics, Inc.	NEW	+304.0K	304.0K	+$23M	$23M
BDQM Albireo Pharma, Inc.	NEW	+518.3K	518.3K	+$15M	$15M
EQ Equillium Inc.	NEW	+4.45M	4.45M	+$14M	$14M
PACB Pacific Biosciences of California, Inc.	NEW	+1.46M	1.46M	+$13M	$13M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2022

24 positions

Export to Excel

#	Issuer	Class	% Portfolio	Value ↓	Shares
1	HLTHQ Cue Health Inc.history →	COM	17.75%	$58M	8.98M
2	ILMN Illumnia, Inc.history →	COM	16.52%	$54M	154.2K
3	NVLSEUR Alpine Immune Sciences, Inc.history →	COM	12.94%	$42M	4.71M
4	Arcus BioSciences, Inc.	COM	8.41%	$27M	869.8K
5	10x Genomics, Inc.	CL A COM	7.09%	$23M	304.0K
6	BDQM Albireo Pharma, Inc.history →	COM	4.74%	$15M	518.3K
7	EQ Equillium Inc.history →	COM	4.29%	$14M	4.45M
8	PACB Pacific Biosciences of California, Inc.history →	COM	4.08%	$13M	1.46M
9	TORCEUR Adicet Bio, Inc.history →	COM	3.55%	$12M	580.0K
10	BeyondSpring Inc.	SHS	3.34%	$11M	4.96M
11	SMFRUSD Sema4 Holings Corp.history →	COM CL A	3.22%	$10M	3.42M
12	Prometheus Biosciences, Inc.	COM	2.89%	$9M	250.0K
13	WHWK Aadi Bioscience, Inc.history →	COM	2.74%	$9M	526.3K
14	AURA Aura Biosciences, Inc.history →	COM	1.42%	$5M	210.0K
15	Checkmate Pharamaceuticals, Inc.	COM	1.30%	$4M	1.33M
16	Owlet, Inc.	COM CL A	1.23%	$4M	898.4K
17	Mersana Therapeutics, Inc.	COM	1.11%	$4M	904.3K
18	AtriCure Inc.	COM	0.93%	$3M	46.3K
19	SCYXEUR Scynexis Inc.	COM NEW	0.67%	$2M	555.6K
20	430 Terns Pharmaceuticals, Inc.	COM	0.65%	$2M	714.3K
21	NeuBase Therapeutics, Inc.	COM	0.58%	$2M	1.00M
22	NAUT Nautilus Biotechnology, Inc.	COM	0.40%	$1M	300.0K
23	MASS 908 Devices Inc.	COM	0.12%	$380,000	20.0K
24	Singular Genomics Systems, Inc.	COM	0.04%	$126,000	20.0K

Filing History

Quarter	Reported Value	Positions	Filed	Type	Links
Q4 2023	$300M	26	Dec 12, 2023	RESTATEMENT	changes · EDGAR ↗
Q3 2023	$313M	27	Nov 29, 2023	RESTATEMENT	changes · EDGAR ↗
Q2 2023	$319M	25	Jul 28, 2023	13F-HR	changes · EDGAR ↗
Q1 2023	$248M	24	May 10, 2023	13F-HR	changes · EDGAR ↗
Q4 2022	$267M	26	Feb 9, 2023	13F-HR	changes · EDGAR ↗
Q3 2022	$276M	26	Nov 8, 2022	13F-HR	changes · EDGAR ↗
Q2 2022	$264M	25	Aug 1, 2022	13F-HR	changes · EDGAR ↗
Q1 2022	$326M	24	May 10, 2022	13F-HR	changes · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.